Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Пограничные состояния в дерматоонкологии

https://doi.org/10.33667/2078-5631-2021-34-49-59

Полный текст:

Аннотация

В данной обзорной статье представлены общие сведения об этиологии, патогенезе, клинической картине, диагностике, а также методах лечения таких заболеваний, как актинический кератоз, кератоакантома и болезнь Боуэна. Подробно описаны провоцирующие факторы, вызывающие данные нозологии, где основное значение придается инсоляции, предшествующей иммуносупрессии и иммунодефицитным состояниям, а также травматизации. Патогенез данных заболеваний описан в виде каскадных моделей. Представлены различные клинические формы и их основные дерматоскопические признаки, пригодные для цифровой обработки в автоматизированных диагностических системах. Описан ступенчатый подход в лечении данных нозологий, а также оценивается предварительный прогноз на основе длительности прогрессирования и вероятности трансформации в плоскоклеточный рак кожи. Учитывая тот факт, что дерматоонкологи до сих не пришли к единому мнению о классификации описанных заболеваний, в данной статье они рассматриваются как пограничные, демонстрируя тем самым тонкую грань перехода из предракового состояния в рак in situ.

Об авторах

С. П. Селезнев
ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М. Ф. Владимирского»
Россия

Селезнев Сергей Павлович, врач-онколог

Москва

 



О. Б. Тамразова
ФГАОУ ВО «Российский университет дружбы народов»
Россия

Тамразова Ольга Борисовна, д. м. н., проф. кафедры дерматовенерологии

Москва



В. Ю. Сергеев
ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ
Россия

Сергеев Василий Юрьевич, к. м. н., доцент кафедры дерматовенерологии и косметологии

Москва



В. Г. Никитаев
ФГАОУ ВО «Национальный исследовательский ядерный университет „МИФИ“»
Россия

Никитаев Валентин Григорьевич, д. т. н., проф., зав. кафедрой компьютерных медицинских систем

Москва



А. Н. Проничев
ФГАОУ ВО «Национальный исследовательский ядерный университет „МИФИ“»
Россия

Проничев Александр Николаевич, к. т. н., доцент отделения биотехнологий офиса образовательных программ

Москва



Список литературы

1. Waldman A., & Schmults C. (2019). Cutaneous Squamous Cell Carcinoma. Hematology. Oncology Clinics of North America, 33 pp 1–2.

2. Thompson A. K., Kelley B. F., Prokop L J., Murad M. H., & Baum C. L. (2016). Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death. JAMA Dermatology, 152 (4), 419. DOI: 10.1001/jamadermatol.2015.4994.

3. WHO Classification of Tumours, 4th Edition, Volume 11. Edited by Elder DE, Massi D, Scolyer RA, Willemze R. 2018.

4. Kirby JS, Scharnitz T, Seiverling EV, Ahrns H, Ferguson S. Actinic Keratosis Clinical Practice Guidelines: An Appraisal of Quality. Dermatol Res Pract. 2015; 2015: 456071. DOI: 10.1155/2015/456071.

5. Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol. 2012 May-Jun; 87 (3): 425–34. DOI: 10.1590/s0365–05962012000300012. PMID: 22714759.

6. Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol. 2000 Jul; 43 (1 Pt 1): 138–50. DOI: 10.1067/mjd.2000.107497. PMID: 10863242.

7. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma («actinic keratosis»). J Am Acad Dermatol. 2000 Jan; 42 (1 Pt 2): 11–7. DOI: 10.1067/mjd.2000.103344. PMID: 10607351.

8. Ishioka P., Marques S. A., Hirai A. T., Marques M. E.A., Hirata S. H., & Yamada S. (2009). Prevalence of precancerous skin lesions and non-melanoma skin cancer in Japanese-Brazilians in Bauru, São Paulo State, Brazil. Cadernos de Saúde Pública, 25 (5), 965–971. DOI: 10.1590/s0102–311x2009000500003.

9. R. Lucas, A. Prüss-Üstün, World Health Organization Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation World Health Organization, Public Health and the Environment, Geneva 2006.

10. Fargnoli MC, Altomare G, Benati E, Borgia F et. all. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. Eur J Dermatol. 2017 Dec 1; 27 (6): 599–608. English. DOI: 10.1684/ejd.2017.3126. PMID: 29311040.

11. Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T. Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J Eur Acad Dermatol Venereol. 2014 Mar; 28 (3): 309–13. DOI: 10.1111/jdv.12102. Epub 2013 Jan 24. PMID: 23347271.

12. Naldi L, Chatenoud L, Piccitto R, Colombo P, Placchesi EB, La Vecchia C; Prevalence of Actinic Keratoses Italian Study (PraKtis) Group. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003–2004. Arch Dermatol. 2006 Jun; 142 (6): 722–6. DOI: 10.1001/archderm.142.6.722. PMID: 16785374.

13. Hensen P, Müller ML, Haschemi R, Ständer H, Luger TA, Sunderkötter C, Schiller M. Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol. 2009 Jul-Aug; 19 (4): 345–54. DOI: 10.1684/ejd.2009.0706. Epub 2009 May 25. PMID: 19470418.

14. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001 Oct; 63 (1–3): 8–18. DOI: 10.1016/s1011–1344(01)00198–1. PMID: 11684447.

15. Ulrich C, Jürgensen JS, Degen A, Hackethal M, et. al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24-months, prospective, case-control study. Br J Dermatol. 2009 Nov;161 Suppl 3: 78–84. DOI: 10.1111/j.1365–2133.2009.09453.x. PMID: 19775361.

16. O’Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011 Aug; 65 (2): 253–261. DOI: 10.1016/j.jaad.2010.11.062. PMID: 21763561.

17. Nashan D, Meiss F, Müller M. Therapeutic strategies for actinic keratoses – a systematic review. Eur J Dermatol. 2013 Jan-Feb; 23 (1): 14–32. DOI: 10.1684/ejd.2013.1923. PMID: 23477760.

18. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002 Jul; 47 (1): 1–17; quiz 18–20. DOI: 10.1067/mjd.2002.125579. PMID: 12077575.

19. Wallingford SC, Russell SA, Vail A, Proby CM, Lear JT, Green AC. Actinic keratoses, actinic field change and associations with squamous cell carcinoma in renal transplant recipients in Manchester, UK. Acta Derm Venereol. 2015 Sep; 95 (7): 830–4. DOI: 10.2340/00015555–2098. PMID: 25784002.

20. Yaldiz M. Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Medicine (Baltimore). 2019; 98 (28): e16465. DOI: 10.1097/MD.0000000000016465.

21. Spencer J. Understanding actinic keratosis: epidemiology, biology, and management of the disease. J Am Acad Dermatol. 2013 Jan; 68 (1 Suppl 1): S 1. DOI: 10.1016/j.jaad.2012.10.006. PMID: 23228300.

22. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013 Jan; 68 (1 Suppl 1): S 10–9. DOI: 10.1016/j.jaad.2012.09.053. PMID: 23228301.

23. Wang L, Eng W, Cockerell CJ. Effects of ultraviolet irradiation on inflammation in the skin. Adv Dermatol. 2002; 18: 247–86. PMID: 12528408.

24. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer. 2004 Jan; 4 (1): 23–35. DOI: 10.1038/nrc1253. PMID: 14681688.

25. Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J. UV-induced squamous cell carcinoma – a role for antiapoptotic signalling pathways. Br J Dermatol. 2009 Nov; 161 Suppl 3: 107–15. DOI: 10.1111/j.1365–2133.2009.09458.x. PMID: 19775366.

26. D’Costa AM, Robinson JK, Maududi T, Chaturvedi V, Nickoloff BJ, Denning MF. The proapoptotic tumor suppressor protein kinase C-delta is lost in human squamous cell carcinomas. Oncogene. 2006 Jan 19; 25 (3): 378–86. DOI: 10.1038/sj.onc.1209065. PMID: 16158048.

27. Heck DE, Gerecke DR, Vetrano AM, Laskin JD. Solar ultraviolet radiation as a trigger of cell signal transduction. Toxicol Appl Pharmacol. 2004 Mar 15; 195 (3): 288–97. DOI: 10.1016/j.taap.2003.09.028. PMID: 15020191.

28. Васенова В. Ю., Бутов Ю. С., Иванова М. С. Особенности патогенеза, клинической картины и лечения актинического кератоза. Российский журнал кожных и венерических болезней. 2017. № 1. Vasenova V. Yu., Butov Yu.S., Ivanova M. S. Features of the pathogenesis, clinical picture and treatment of actinic keratosis. Russian Journal of Skin and Venereal Diseases. 2017. No. 1.

29. Kato J, Horimoto K, Sato S, Minowa T, Uhara H. Dermoscopy of Melanoma and Non-melanoma Skin Cancers. Front Med (Lausanne). 2019 Aug 21; 6: 180. DOI: 10.3389/fmed.2019.00180. PMID: 31497603; PMCID: PMC 6712997.

30. Peris K, Micantonio T, Piccolo D, Fargnoli MC. Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges. 2007 Nov; 5(11): 970–6. English, German. DOI: 10.1111/j.1610–0387.2007.06318.x. Epub 2007 Oct 1. PMID: 17908179.

31. Abudu B, Calame A, Cohen PR. Pigmented Actinic Keratosis: Case Report and Review of an Uncommon Actinic Keratosis Variant that can Mimic Melanoma. Cureus. 2019 May 22; 11 (5): e4721. DOI: 10.7759/cureus.4721. PMID: 31355081; PMCID: PMC 6650181.

32. Butani AK, Arbesfeld DM, Schwartz RA. Premalignant and early squamous cell carcinoma. Clin Plast Surg. 2005 Apr; 32 (2): 223–35. DOI: 10.1016/j.cps.2004.11.001. Erratum in: Clin Plast Surg. 2006 Jul; 33 (3): 497. PMID: 15814119.

33. Bakshi A, Shafi R, Nelson J, Cantrell WC, Subhadarshani S, Andea A, Athar M, Elmets CA. The clinical course of actinic keratosis correlates with underlying molecular mechanisms. Br J Dermatol. 2020 Apr; 182 (4): 995–1002. DOI: 10.1111/bjd.18338. Epub 2019 Sep 11. PMID: 31299087; PMCID: PMC 7309433.

34. Martín JM, Bella-Navarro R, Jordá E. Vascularización en dermatoscopia [Vascular patterns in dermoscopy]. Actas Dermosifiliogr. 2012 Jun; 103 (5): 357–75. Spanish. DOI: 10.1016/j.ad.2011.11.005. Epub 2012 Mar 29. PMID: 22463770.

35. Kittler H, Marghoob AA, Argenziano G, Carrera C, Curiel-Lewandrowski C et. all. Standardization of terminology in dermoscopy/dermatoscopy: Results of the third consensus conference of the International Society of Dermoscopy. J Am Acad Dermatol. 2016 Jun; 74 (6): 1093–106. DOI: 10.1016/j.jaad.2015.12.038. Epub 2016 Feb 17. PMID: 26896294; PMCID: PMC 5551974.

36. Zalaudek I, Giacomel J, Schmid K et, all. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J Am Acad Dermatol. 2012 Apr; 66 (4): 589–97. DOI: 10.1016/j.jaad.2011.02.011. Epub 2011 Aug 11. PMID: 21839538.

37. Moscarella, E., Rabinovitz, H., Zalaudek, I. et. all. (2014). Dermoscopy and reflectance confocal microscopy of pigmented actinic keratoses: a morphological study. Journal of the European Academy of Dermatology and Venereology, 29 (2), 307–314. DOI: 10.1111/jdv.12532

38. Casari A, Chester J, Pellacani G. Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. Biomedicines. 2018 Jan 8; 6 (1): 8. DOI: 10.3390/biomedicines6010008. PMID: 29316678; PMCID: PMC 5874665.

39. Werner RN, Jacobs A, Rosumeck S, Erdmann R, Sporbeck B, Nast A. Methods and Results Report – Evidence and consensus-based (S 3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum. J Eur Acad Dermatol Venereol. 2015 Nov; 29 (11): e1–66. DOI: 10.1111/jdv.13179. Epub 2015 Sep 9. PMID: 26350885.

40. Vieira RA, Minicucci EM, Marques ME, Marques SA. Actinic cheilitis and squamous cell carcinoma of the lip: clinical, histopathological and immunogenetic aspects. An Bras Dermatol. 2012 Jan-Feb; 87 (1): 105–14. DOI: 10.1590/s0365–05962012000100013. PMID: 22481658.

41. Nascimento MM, Shitara D, Enokihara MM et. All. Inner gray halo, a novel dermoscopic feature for the diagnosis of pigmented actinic keratosis: clues for the differential diagnosis with lentigo maligna. J Am Acad Dermatol. 2014 Oct; 71 (4): 708–15. DOI: 10.1016/j.jaad.2014.05.025. Epub 2014 Jun 17. PMID: 24947988.

42. Lallas A, Argenziano G, Moscarella E, Longo C, Simonetti V, Zalaudek I. Diagnosis and management of facial pigmented macules. Clin Dermatol. 2014 Jan-Feb; 32 (1): 94–100. DOI: 10.1016/j.clindermatol.2013.05.030. PMID: 24314382.

43. Chong A. H., Sinclair R. Actinic Keratoses. In: Treatment of Skin Disease. Comprehensive therapeutic strategies 2nd Ed. by M. G. Lebwohl, W. R. Haymann et al. Mosby, 2006: 14–16.

44. В. А. Молочков, Ю. В. Молочкова. Дерматоонкология: лечение. Практическая медицина. Москва. 2018, с. 224. V. A. Molochkov, Yu. V. Molochkova. Dermato-oncology: treatment. Practical medicine. Moscow. 2018, p. 224.

45. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009 Jun 1; 115 (11): 2523–30. DOI: 10.1002/cncr.24284. PMID: 19382202.

46. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013 Sep; 169 (3): 502–18. DOI: 10.1111/bjd.12420. PMID: 23647091.

47. Beatson M, Siegel JA, Chren MM, Weinstock MA. Effects of increased actinic keratosis count on skin-related quality of life: results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial. Eur J Dermatol. 2019 Oct 1; 29 (5): 507–510. DOI: 10.1684/ejd.2019.3637. PMID: 31647464.

48. Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol. 2009 Aug; 26 (3): 150–63. DOI: 10.1053/j.semdp.2009.09.003. PMID: 20043514.

49. Hutchinson J. A. Morbid growths and tumors: the crateriform ulcer of the face, a form of acute epithelial cancer. Trans Pathol Soc London. 1889; 40: 275–281.

50. Choonhakarn, Charoen & Ackerman, A. B. Keratoacanthomas: A new classification based on morphologic findings and on anatomic site. Dermatopathol Pract Concept. 7. 2001. 7–16.

51. Dupont A: Kystes sébacés végétans, kératoacanthomes, verrucomes. Bull Soc Fr Dermatolol Syphiligr 59: 340, 1952. 5.

52. MacCormac H, Scarff RW: Molluscum sebaceum. Br J Dermatol 1936; 48: 624–6276.

53. Halnan K. E. Molluscum pseudocarcinomatosum. Lancet. 1953 Dec 26; 265 (6800): 1358. DOI: 10.1016/s0140–6736(53)91287–2. PMID: 13110177.

54. Rook A.J, Whimster I.W: Le kératoacanthome. Arch Belg Dermatol Syph 6: 137–146, 1950.

55. Rook A.J, Whimster I.W: Keratoacanthoma – A thirty-year retrospect. Br J Dermatol 100: 41–47, 1979.

56. Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007 Jul; 46 (7): 671–8. DOI: 10.1111/j.1365–4632.2007.03260.x. PMID: 17614793.

57. Zito PM, Scharf R. Keratoacanthoma. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan.

58. Majores M, Bierhoff E. Aktinische Keratose, Morbus Bowen, Keratoakanthom und Plattenepithelkarzinom der Haut [Actinic keratosis, Bowen’s disease, keratoacanthoma and squamous cell carcinoma of the skin]. Pathologe. 2015 Feb; 36 (1): 16–29. German. DOI: 10.1007/s00292–014–2063–3. PMID: 25663185.

59. Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol. 2016 Jun; 74 (6): 1220–33. DOI: 10.1016/j.jaad.2015.11.033. Epub 2016 Feb 4. PMID: 26853179.

60. Quinn Adam, et al. Eruptive keratoacanthomas in tattoos. Australasian Journal of Dermatology 58.4 (2017): 317–318.

61. Богомолова И. А., Антонеева И. И., Долгова Д. Р. Клинические особенности течения колоректального рака у пациентов с мутациями генов EGFR-сигнального пути. Ульяновский медико-биологический журнал. 2019. № 1. Bogomolova I. A., Antoneeva I. I., Dolgova D. R. Clinical features of the course of colorectal cancer in patients with mutations in the EGFR signaling pathway genes. Ulyanovsk Medical and Biological Journal. 2019. No. 1.

62. Cristalli MP, Marini R, LA Monaca G, Vitolo D, Pompa G, Annibali S. Double localization of keratoacantho-ma on the cutaneous and mucosal sides of the lower lip: report of a case. Oral Implantol (Rome). 2014 May 19; 6 (4): 94–8. PMID: 24971163; PMCID: PMC 4051273.

63. Lin MJ, Pan Y, Jalilian C, Kelly JW. Dermoscopic characteristics of nodular squamous cell carcinoma and keratoacanthoma. Dermatol Pract Concept. 2014 Apr 30; 4 (2): 9–15. DOI: 10.5826/dpc.0402a02. PMID: 24855567; PMCID: PMC 4029247.

64. Higgins JC, Maher MH, Douglas MS. Diagnosing Common Benign Skin Tumors. Am Fam Physician. 2015 Oct 1; 92 (7): 601–7. PMID: 26447443.

65. Bedir R, Güçer H, Şehitoğlu İ, et all. The Role of p16, p21, p27, p53 and Ki‑67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study. Balkan Med J. 2016 Mar; 33 (2): 121–7. DOI: 10.5152/balkanmedj.2016.16442. Epub 2016 Mar 1. PMID: 27403379; PMCID: PMC 4924954.

66. Chaser BE, Renszel KM, Crowson AN et. All. Onycholemmal carcinoma: a morphologic comparison of 6 reported cases. J Am Acad Dermatol. 2013 Feb; 68 (2): 290–5. DOI: 10.1016/j.jaad.2012.07.015. Epub 2012 Aug 20. PMID: 22917894.

67. LaPresto L, Cranmer L, Morrison L, et. All. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil. JAMA Dermatol. 2013 Mar; 149 (3): 279–81. DOI: 10.1001/jamadermatol.2013.2583. PMID: 23552479; PMCID: PMC 4575122.

68. Carr RA, Taibjee SM, Turnbull N, Attili S. Follicular squamous cell carcinoma is an under-recognized common skin tumor. Diag Histopathol. 2014; 20: 289–296.

69. Griffiths RW. Keratoacanthoma observed. Br J Plast Surg. 2004 Sep; 57 (6): 485–501. DOI: 10.1016/j.bjps.2004.05.007. PMID: 15308394.

70. Hu SC, Chiu HH, Chen GS, Ke CL, Cheng ST. Dermoscopy as a diagnostic and follow-up tool for pigmented Bowen’s disease on acral region. Dermatol Surg. 2008 Sep; 34 (9): 1248–53; discussion 1253. DOI: 10.1111/j.1524–4725.2008.34269.x. Epub 2008 Jun 12. PMID: 18554290.

71. Lee M. M., & Wick M. M. (1990). Bowen’s disease. CA: A Cancer Journal for Clinicians, 40 (4), 237–242. DOI: 10.3322/canjclin.40.4.237.

72. Lee M. M., & Wick M. M. (1993). Bowen’s disease. Clinics in Dermatology, 11 (1), 43–46.

73. Bath-Hextall F.J., Matin R. N., Wilkinson D., & Leonardi-Bee J. (2013). Interventions for cutaneous Bowen’s disease. Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.cd007281.pub2.

74. Shimizu A, Tamura A, Abe M, Amano H, Motegi S, Nakatani Y, Hoshino H, Ishikawa O. Human papillomavirus type 56-associated Bowen disease. Br J Dermatol. 2012 Nov; 167 (5): 1161–4. DOI: 10.1111/j.1365–2133.2012.11071.x. PMID: 22630056.

75. Cox NH, Eedy DJ, Morton CA; Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists. Guidelines for management of Bowen’s disease: 2006 update. Br J Dermatol. 2007 Jan; 156 (1): 11–21. DOI: 10.1111/j.1365–2133.2006.07610.x. PMID: 17199561.

76. Lee CH, Yu HS. Role of mitochondria, ROS, and DNA damage in arsenic induced carcinogenesis. Front Biosci (Schol Ed). 2016 Jun 1; 8: 312–20. DOI: 10.2741/s465. PMID: 27100709.

77. Lallas A, Argenziano G, Zendri E, et.all. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther. 2013 May; 13 (5): 541–58. DOI: 10.1586/era.13.38. PMID: 23617346.

78. Baker BA, Cassano VA, Murray C; ACOEM Task Force on Arsenic Exposure. Arsenic Exposure, Assessment, Toxicity, Diagnosis, and Management: Guidance for Occupational and Environmental Physicians. J Occup Environ Med. 2018 Dec; 60 (12): e634–e639. DOI: 10.1097/JOM.0000000000001485. PMID: 30358658.

79. Hsueh YM, Huang YL, Huang CC et. all. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A. 1998 Jul 24; 54 (6): 431–44. DOI: 10.1080/009841098158728. PMID: 9661909.

80. Huang YK, Huang YL, Hsueh YM et. All. Changes in urinary arsenic methylation profiles in a 15-year interval after cessation of arsenic ingestion in southwest Taiwan. Environ Health Perspect. 2009 Dec; 117 (12): 1860–6. DOI: 10.1289/ehp.0900560. Epub 2009 Jul 29. PMID: 20049204; PMCID: PMC 2799459.

81. Chanda S, Dasgupta UB, Guhamazumder D et. All. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol Sci. 2006 Feb; 89 (2): 431–7. DOI: 10.1093/toxsci/kfj030. Epub 2005 Oct 26. PMID: 16251483.

82. Zhou X, Sun H, Ellen TP et.all. Arsenite alters global histone H3 methylation. Carcinogenesis. 2008 Sep; 29 (9): 1831–6. DOI: 10.1093/carcin/bgn063. Epub 2008 Mar 4. PMID: 18321869; PMCID: PMC 2722848.

83. Ribero S, Mangino M, Bataille V. Skin phenotypes can offer some insight about the association between telomere length and cancer susceptibility. Med Hypotheses. 2016 Dec; 97: 7–10. DOI: 10.1016/j.mehy.2016.10.010. Epub 2016 Oct 19. PMID: 27876133.

84. Yamada-Hishida H, Nobeyama Y, Nakagawa H. Correlation of telomere length to malignancy potential in non-melanoma skin cancers. Oncol Lett. 2018 Jan; 15 (1): 393–399. DOI: 10.3892/ol.2017.7278. Epub 2017 Oct 26. PMID: 29285197; PMCID: PMC 5738687.

85. Lee C.-H., Wu S.-B., Hong, et. al. (2013). Involvement of mtDNA Damage Elicited by Oxidative Stress in the Arsenical Skin Cancers. Journal of Investigative Dermatology, 133 (7), 1890–1900. DOI: 10.1038/jid.2013.55.

86. Lee CH, Wu SB, Hong CH, et al. Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers. Am J Pathol. 2011 May; 178 (5): 2066–76. DOI: 10.1016/j.ajpath.2011.01.056. PMID: 21514422; PMCID: PMC 3081159.

87. Samper E, Morgado L, Estrada JC, et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med. 2009 Feb 1; 46 (3): 387–96. DOI: 10.1016/j.freeradbiomed.2008.10.036. Epub 2008 Oct 30. PMID: 19038329; PMCID: PMC 2665299.

88. Wen G, Calaf GM, Partridge MA et al. Neoplastic transformation of human small airway epithelial cells induced by arsenic. Mol Med. 2008 Jan-Feb; 14 (1–2): 2–10. DOI: 10.2119/2007–00090.Wen. PMID: 18037969; PMCID: PMC 2082132.

89. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013 Aug 1; 3 (8): a014217. DOI: 10.1101/cshperspect.a014217. PMID: 23906881; PMCID: PMC 3721271.

90. C. H. Ussakli, A. Ebaee, J. Binkley, et al: Mitochondria and tumor progression in ulcerative colitis. J Natl Cancer Inst, 105 (16), 1239–48 (2013).

91. Ferrándiz, C., Malvehy, J., Guillén, C., Ferrándiz-Pulido, C., & Fernández-Figueras, M. (2017). Precáncer cutáneo. Actas Dermo-Sifiliográficas, 108 (1), 31–41. DOI: 10.1016/j.ad.2016.07.016.

92. Lallas A, Argenziano G, Zendri E et. All. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther. 2013 May; 13 (5): 541–58. DOI: 10.1586/era.13.38. PMID: 23617346.

93. Stamm AW, Kobashi KC, Stefanovic KB. Urologic Dermatology: A Review. Curr Urol Rep. 2017 Aug; 18 (8): 62. DOI: 10.1007/s11934–017–0712–9. PMID: 28667573.

94. Payapvipapong K, Tanaka M. Dermoscopic classification of Bowen’s disease. Australas J Dermatol. 2015 Feb; 56 (1): 32–5. DOI: 10.1111/ajd.12200. Epub 2014 Oct 21. PMID: 25330999.

95. Kato J, Horimoto K, Sato S, Minowa T, Uhara H. Dermoscopy of Melanoma and Non-melanoma Skin Cancers. Front Med (Lausanne). 2019 Aug 21; 6: 180. DOI: 10.3389/fmed.2019.00180. PMID: 31497603; PMCID: PMC 6712997.

96. Paolino G, Donati M, Didona D, Mercuri SR, Cantisani C. Histology of Non-Melanoma Skin Cancers: An Update. Biomedicines. 2017 Dec 20; 5 (4): 71. DOI: 10.3390/biomedicines5040071. PMID: 29261131; PMCID: PMC 5744095.

97. В. Г. Никитаев, О. Б. Тамразова, А. Н. Проничев, В. Ю. Сергеев, Е. А. Дружинина. Алгоритм анализа характеристик пигментной сети в диагностике меланомы. Матем. моделирование, 33: 2 (2021), 67–81. V. G. Nikitaev, O. B. Tamrazova, A. N. Pronichev, V. Yu. Sergeev, E. A. Druzhinin. Algorithm for analyzing the characteristics of the pigment network in the diagnosis of melanoma. Mat. Modeling, 33: 2 (2021), 67–81.

98. В. Г. Никитаев, А. Н. Проничев, О. Б. Тамразова, В. Ю. Сергеев, О. А. Медведева, М. А. Соломатин. Визуализация изображений новообразований кожи для экспертных систем диагностики меланомы. Приборы. 2021; 2: 41–45. V. G. Nikitaev, A. N. Pronichev, O. B. Tamrazova, V. Yu. Sergeev, O. A. Medvedeva, M. A. Solomatin. Visualization of images of skin neoplasms for expert systems for the diagnosis of melanoma. Devices. 2021; 2: 41–45.


Рецензия

Для цитирования:


Селезнев С.П., Тамразова О.Б., Сергеев В.Ю., Никитаев В.Г., Проничев А.Н. Пограничные состояния в дерматоонкологии. Медицинский алфавит. 2021;(34):49-59. https://doi.org/10.33667/2078-5631-2021-34-49-59

For citation:


Seleznev S.P., Tamrazova O.B., Sergeev V.Yu., Nikitaev V.G., Pronichev A.N. Borderline conditions in dermato-oncology. Medical alphabet. 2021;(34):49-59. (In Russ.) https://doi.org/10.33667/2078-5631-2021-34-49-59

Просмотров: 232


ISSN 2078-5631 (Print)